These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 15969877)

  • 1. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
    Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
    Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians.
    Campo S; Sardo MA; Trimarchi G; Bonaiuto M; Fontana L; Castaldo M; Bonaiuto A; Saitta C; Bitto A; Manduca B; Riggio S; Saitta A
    Exp Gerontol; 2004 Jul; 39(7):1089-94. PubMed ID: 15236768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
    Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
    Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
    Himbergen TM; van Tits LJ; Voorbij HA; de Graaf J; Stalenhoef AF; Roest M
    J Intern Med; 2005 Nov; 258(5):442-9. PubMed ID: 16238680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E.
    Cangemi R; Loffredo L; Carnevale R; Perri L; Patrizi MP; Sanguigni V; Pignatelli P; Violi F
    Eur Heart J; 2008 Jan; 29(1):54-62. PubMed ID: 18065424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
    J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia.
    Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Ciani F; Palazzuoli A; Acampa M; Auteri A
    Eur J Clin Invest; 2008 Jan; 38(1):11-6. PubMed ID: 18173546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Samy W; Hassanian MA
    Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
    Dornbrook-Lavender KA; Joy MS; Denu-Ciocca CJ; Chin H; Hogan SL; Pieper JA
    Pharmacotherapy; 2005 Mar; 25(3):335-44. PubMed ID: 15843280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
    Harangi M; Mirdamadi HZ; Seres I; Sztanek F; Molnár M; Kassai A; Derdák Z; Illyés L; Paragh G
    Transl Res; 2009 Apr; 153(4):190-8. PubMed ID: 19304278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
    Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
    Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients.
    Liu CS; Lii CK; Chang LL; Kuo CL; Cheng WL; Su SL; Tsai CW; Chen HW
    Nutr Res; 2010 Feb; 30(2):118-24. PubMed ID: 20226997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status.
    Nagila A; Permpongpaiboon T; Tantrarongroj S; Porapakkham P; Chinwattana K; Deakin S; Porntadavity S
    Pharmacol Rep; 2009; 61(5):892-8. PubMed ID: 19904013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy.
    Rosenblat M; Hayek T; Hussein K; Aviram M
    Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):175-80. PubMed ID: 14592851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging.
    Cherki M; Berrougui H; Isabelle M; Cloutier M; Koumbadinga GA; Khalil A
    Exp Gerontol; 2007 Aug; 42(8):815-24. PubMed ID: 17532162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
    Nordøy A; Hansen JB; Brox J; Svensson B
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):7-16. PubMed ID: 11383326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.